Trial Profile
Efficacy and Safety of Intravenously Administered hzVSF-v13 in Patients With COVID-19 Pneumonia: a Phase II, Proof of Concept, Multicentre, Randomized, Parallel-group, Double-blind, Placebo-controlled Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Aug 2022
Price :
$35
*
At a glance
- Drugs Burfiralimab (Primary)
- Indications COVID-19 pneumonia
- Focus Adverse reactions; Pharmacodynamics; Proof of concept; Therapeutic Use
- Sponsors ImmuneMed
- 29 Nov 2021 Status changed from recruiting to completed.
- 24 Aug 2021 Planned End Date changed from 18 Oct 2021 to 28 Oct 2021.
- 24 Aug 2021 Planned primary completion date changed from 7 Jul 2021 to 29 Aug 2021.